Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma

• Main Authors: Moore, N.F, Azarova, A.M, Bhatnagar, N, Ross, K.N, Drake, L.E, Frumm, S, Liu, Q.S, Christie, A.L, Sanda, T, Chesler, L, Kung, A.L, Gray, N.S, Stegmaier, K, George, R.E
• Other Authors: MEDICINE
• Format: Article
• Published: 2020
• Subjects: 2 morpholino 8 phenylchromone; azd 8055; crizotinib; dactolisib; gedatolisib; mammalian target of rapamycin inhibitor; pictilisib; torin 2; unclassified drug; anaplastic lymphoma kinase; antineoplastic agent; mechanistic target of rapamycin complex 1; MTOR protein, human; multiprotein complex; MYCN protein, human; nuclear protein; oncoprotein; phosphatidylinositol 3 kinase; protein kinase B; protein kinase inhibitor; protein S6; protein tyrosine kinase; pyrazole derivative; pyridine derivative; target of rapamycin kinase; ALK gene; animal experiment; animal model; antineoplastic activity; Article; controlled study; down regulation; drug cytotoxicity; drug megadose; drug potency; drug potentiation; enzyme activity; gene expression profiling; gene mutation; human; human cell; molecularly targeted therapy; mouse; multiple cycle treatment; MYCN gene; neuroblastoma; nonhuman; oncogene; protein phosphorylation; signal transduction; tumor volume; tumor xenograft; upregulation; animal; antagonists and inhibitors; dose response; drug effects; drug resistance; drug screening; enzymology; gene amplification; genetic transfection; genetics; metabolism; mutation; nonobese diabetic mouse; pathology; phosphorylation; RNA interference; SCID mouse; time; tumor cell line; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gene Amplification; Humans; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Multiprotein Complexes; Mutation; Neuroblastoma; Nuclear Proteins; Oncogene Proteins; Phosphatidylinositol 3-Kinase; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Receptor Protein-Tyrosine Kinases; Ribosomal Protein S6; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Transfection; Xenograft Model Antitumor Assays
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/181776
• Institution: National University of Singapore

10.18632/oncotarget.2372